Navigation Links
Baraclude (entecavir) Therapy Resulted in Undetectable Levels of,Hepatitis B Virus in Cohort of Patients Who Re-Started Treatment

nts who discontinued study therapy in ETV-027, and subsequently restarted treatment in rollover study ETV-901, with a greater than 60 day gap between end of treatment in study ETV-027 and start of treatment in study ETV-901.

    -- ETV-027 compared 0.5 mg of BARACLUDE vs. 100 mg of lamivudine in
nucleoside-naive chronic HBeAg-negative chronic hepatitis B patients.
-- Rollover study ETV-901 was established as an open-label, follow-up
protocol for patients in phase II and III studies of BARACLUDE.
-- Due to ongoing blinding of study ETV-027, most patients retreated in
ETV-901 initially received a combination of 1 mg of BARACLUDE plus 100
mg of lamivudine, and were subsequently switched to 1 mg of BARACLUDE
monotherapy.

The analysis cohort was defined regardless of treatment response at the end of dosing in study ETV-027, and independent of virologic or ALT measurements at the start of dosing in study ETV-901. During off-treatment follow-up, the majority of patients had recurrent levels of hepatitis B virus in the blood (viremia) and increases in ALT.

    Data Results
At the end of dosing for study ETV-027:
-- 94 percent (n=93/99) of the re-treatment cohort had undetectable viral
load
-- 78 percent (n=77/99) had ALT normalization
At entry into ETV-901:
-- Four percent (n=4/99) of patients had undetectable viral load
-- Eight percent (n=8/97) of patients had ALT normalization
Following re-treatment in study ETV-901:
-- 93 percent (n=82/88) of patients had undetectable viral load (HBV DNA
<300 copies/mL) by week 48 of re-treatment with BARACLUDE
-- 83 percent (n=79/95) of patients had ALT normalization (ALT less than
or equal to 1 times the upper limit of normal) by week 48 of re-
treatment BARACLUDE
Adverse events in study ETV-027/901 re-treatment cohort:
-- 67 percent (n=66/99) of patients experienced an adverse event. The most
common adverse events occurring in greater than ten percent of patients
were abdominal pain, fa
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load Reduction Compared to Adefovir at 48 Weeks in Study of Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients
2. Gene Chips to Detect CYP Variations: A New Step Toward Customized Medical Therapy.
3. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
4. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
5. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
6. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
7. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
8. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
9. Studies of Drug Resistance May Lead to Individual Therapy for Rare Cancers
10. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
11. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
Post Your Comments:
(Date:8/28/2015)... Aug. 28, 2015 ... addition of the "Investigation Report on China,s ... offering. Developed by Novo Nordisk, insulin ... an important drug for the treatment of diabetes. ... fast- acting insulin analog, starts working fast and ...
(Date:8/28/2015)... Perrigo Company plc ("Perrigo") (NYSE: PRGO ; TASE) ... MYL ) shareholder vote regarding its planned unsolicited offer ... offer to Perrigo shareholders have always been, and will ... of the value available to Perrigo shareholders, and do ... allowed its shareholders to consider," said Joseph C. ...
(Date:8/28/2015)... 2015 The report "Eubiotics Market by Type (Probiotics, ... and Aquaculture), & by Region ( North America ... , and Rest of the World) - Global Trends and ... Eubiotics was valued at USD 4.62 Billion in 2014 and ... a CAGR of 7.4% from 2015 to 2020. ...
Breaking Medicine Technology:China Insulin Aspart Market Report 2010-2019 - Developed by Novo Nordisk 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5Eubiotics Market Worth 7.05 Billion USD by 2020 2Eubiotics Market Worth 7.05 Billion USD by 2020 3Eubiotics Market Worth 7.05 Billion USD by 2020 4Eubiotics Market Worth 7.05 Billion USD by 2020 5
... Merrimack Pharmaceuticals, Inc. announced today that the first ... study combining MM-121, a fully human monoclonal antibody that ... for patients with advanced solid tumors. ... evaluates the safety and pharmacokinetics of MM-121 when administered ...
... LLC has hired nutritional brand marketing expert Tom Hall ... will apply his 30 years of executive marketing experience ... to launch new company products in the international marketplace. ... "Tom,s extensive experience and success in product ...
Cached Medicine Technology:Tom Hall Named National Sales and Marketing Director for VR Laboratories 2Tom Hall Named National Sales and Marketing Director for VR Laboratories 3
(Date:8/29/2015)... ... August 30, 2015 , ... Rio Salado College President Chris ... college’s Vice President of Strategic Initiatives and Information Services. O’Shea, who has served Rio ... expand its reach and impact through innovative technologies and strategies. , “I am very ...
(Date:8/29/2015)... ... August 29, 2015 , ... On Saturday, September 19, 2015, Diane Blackburn-Zambetti, ... (Meso Foundation) will present an educational program titled “Asbestos and Your Health.” , ... 9:30 PM (doors open at 6:45pm) at Calvary United Methodist Church, 16 E Park ...
(Date:8/29/2015)... ... August 29, 2015 , ... Targeted therapies, made ... the lives of patients, according to a newly published report. Surviving Mesothelioma has ... full article. , The authors of the new paper focus on several ...
(Date:8/29/2015)... NY (PRWEB) , ... August 29, 2015 , ... Next ... end of summer (which astronomically, officially ends on September 22nd this year). For IT ... cyber security hangovers linger on which could prove far more costly than a simple ...
(Date:8/29/2015)... ... August 29, 2015 , ... Hamstring strain ... stretching, soft tissue manipulation. Platelet rich plasma injections also have mixed results. ... improve treatment outcomes. This localized treatment seems to address the symptoms and ...
Breaking Medicine News(10 mins):Health News:Rio Salado College Appoints New Vice President of Strategic Initiatives and Information Services 2Health News:Mesothelioma Applied Research Foundation to Hold Educational Class About Asbestos and Mesothelioma Prevention 2Health News:Top Mesothelioma Researchers Highlight Targeted Therapies in New Report, According to Surviving Mesothelioma 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 3Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 4Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 3
... until it encounters a cancer cell, then suddenly activates and ... marks the latest step in scientists, efforts to tap the ... of the technology at the University of Rochester Medical Center ... machines produced in abundance by tumors to chew through and ...
... a major public health problem through its association with ... life expectancy rises around the world, along with the ... incidence of hip fractures is estimated to reach 6.3 ... of fracture in men and women. A new review ...
... on the words ,light, and ,mild, smokers in Western ... may be less harmful than others. In fact, ... of risk to smokers, including ,mild, and ,low-tar, brands. ... Addiction polled over 8000 smokers from Australia, Canada, ...
... Amanda Gardner HealthDay Reporter , MONDAY, April 11 ... primary care doctors often choose a different option than they ... In fact, physicians who were surveyed in the research more ... to have long-term repercussions, such as paralysis, than to die. ...
... University researcher has co-authored an international study that revealed a ... treat a rare lung disease in women. The life-threatening ... The clinical trial of the drug -- called sirolimus ... a therapy for the lung disease, lymphangioleiomyomatosis, or LAM. ...
... -- Long-term use of antibiotics to treat acne doesn,t ... medications, a new study finds. The finding came ... of antibiotics has been credited with encouraging antibiotic resistance ... Pennsylvania School of Medicine assessed the prevalence of ...
Cached Medicine News:Health News:A 'Pacman strategy' to boost the immune system to fight cancer 2Health News:A 'Pacman strategy' to boost the immune system to fight cancer 3Health News:Changing trends in hip fracture incidence around the world 2Health News:Smokers believe 'silver', 'gold' and 'slim' cigarettes are less harmful 2Health News:Doctors Often Wouldn't Follow Their Own Advice: Study 2Health News:Doctors Often Wouldn't Follow Their Own Advice: Study 3Health News:OHSU expert co-authors study finding treatment for rare lung disease 2Health News:Acne Antibiotics Not Linked to Drug Resistance 2
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
... a monopolar cautery connector extending from the ... used for electrosurgery when properly attached to ... ,Ethicon Endo-Surgery provides disposable handheld instruments ... Our handheld instruments come in 5mm and ...
... The Featured Products ... at Mediflex and are ... modular in regular or ... come equipped with insulation, ...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
Medicine Products: